Garofalo Health Care Valuation
Is GHC undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of GHC when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: GHC (€5.9) is trading below our estimate of fair value (€8.24)
Significantly Below Fair Value: GHC is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for GHC?
Key metric: As GHC is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is GHC's PE Ratio? | |
|---|---|
| PE Ratio | 25x |
| Earnings | €20.92m |
| Market Cap | €522.52m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 1.7x |
| Enterprise Value/EBITDA | 10.2x |
| PEG Ratio | 2.3x |
Price to Earnings Ratio vs Peers
How does GHC's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 24.7x | ||
GPI GPI | 36.2x | 35.2% | €323.8m |
ELN EL.En | 19x | 8.3% | €974.4m |
SRI Servizi Italia | 14.7x | 16.9% | €68.7m |
PR9 Praram 9 Hospital | 28.9x | 11.4% | ฿20.1b |
GHC Garofalo Health Care | 25x | 11.0% | €522.5m |
Price-To-Earnings vs Peers: GHC is expensive based on its Price-To-Earnings Ratio (25x) compared to the peer average (24.7x).
Price to Earnings Ratio vs Industry
How does GHC's PE Ratio compare vs other companies in the European Healthcare Industry?
| 2 Companies | Price / Earnings | Estimated Growth | Market Cap |
|---|---|---|---|
| 2 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Earnings vs Industry: GHC is expensive based on its Price-To-Earnings Ratio (25x) compared to the European Healthcare industry average (18.5x).
Price to Earnings Ratio vs Fair Ratio
What is GHC's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 25x |
| Fair PE Ratio | 17.1x |
Price-To-Earnings vs Fair Ratio: GHC is expensive based on its Price-To-Earnings Ratio (25x) compared to the estimated Fair Price-To-Earnings Ratio (17.1x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Fresenius Medical Care
€12.4b
Provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally.
1FME
€42.31
7D
1.2%
1Y
18.1%
Amplifon
€5.2b
Engages in the distribution of hearing solutions and the fitting of customized products that help people rediscover various emotions of sound in Europe, the Middle East, Africa, the Americas, and the Asia Pacific.
AMP
€23.24
7D
-2.1%
1Y
-18.2%
EL.En
€974.4m
Engages in the research and development, planning, manufacture, and sale of laser systems in Italy, rest of Europe, and internationally.
ELN
€12.17
7D
4.8%
1Y
25.9%